您当前的位置：首页 >> 聚焦 >  >> 
每日时讯!招银证券：给予瑞科生物-B(02179.HK)“增持”评级 目标价20.96港元
来源: 同花顺金融研究中心      时间：2023-05-30 15:15:32


(资料图片)

招银证券5月30日发布公告。Maintain BUY. In May 2023, the Company has been selected as a constituent of the MSCI China Small Cap Index. Recbio reported RMB722.7mn net attributable loss for 2022, vs RMB657.6mn net attributable loss in 2021. R&D expense increased by 51.5% YoY to RMB716.4mn in 2022, mainly due to clinical trial expenses related to the expansion of scope of ReCOV clinical trials and Ph III trial of REC603. Given the declining demand for COVID vaccines and intensifying competition among domestic COVID vaccines, we lowered our estimates on ReCOV. We revised our TP from HK$38.86 to HK$20.96 (WACC: 10.6%, terminal growth rate: 2.5%).

标签：

上一篇：拜登、麦卡锡达成“妥协”，却导致两党内部不满，无人欢呼！ 当前关注

下一篇：最后一页

精彩推送

X 关闭

电视剧

X 关闭

电影

热播

推荐阅读